Supriya Lifescience LtdQ1 FY27
Supriya Lifescience Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹776P/E: 32.6Market Cap: ₹6.5K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Supriya Lifescience targets a revenue of Rs. 1,000 crores by FY '27, reflecting strong demand and robust product pipeline.
- →The company expects a CAGR growth of about 20% year-on-year beyond FY '27, supported by new products and capacity expansions.
- →Q1 FY '27 revenue was Rs. 190 crores, showing 31% YoY growth despite water scarcity issues.
- →Growth is anticipated to accelerate in the second half of FY '27 due to scaling-up of liquid anesthetic products, cardiovascular drugs, and launch of contrast media products.
- →Continued addition of new products, new therapy verticals, and CMO-CDMO collaborations at API and formulation levels will support sustained growth.
- →Expansion at Ambernath facility (finished formulations) and capacity building at the Patalganga plant also underpin future growth.
- →Growth may exceed 20%, subject to regulatory approvals and successful commercial ramp-ups.
Margin guidance
Category 3- →Supriya Lifescience targets a revenue of around Rs. 1,000 crores by FY '27, reflecting strong demand and new product launches.
- →Management anticipates maintaining EBITDA margins in the range of 33% to 35% over the next 3-4 years.
- →PAT margin guidance stands around 25%.
- →Growth expected to be non-linear quarterly but robust over the medium term, supported by new therapies, vertical expansions (CMO-CDMO), and capacity additions like Patalganga facility.
- →CAGR growth of about 20% year-on-year expected beyond FY '27, with potential for acceleration depending on regulatory approvals and market traction.
- →Margin expansion beyond current levels unlikely in near term due to CMO-CDMO focus and semi-regulated market scale-up phases.
Fundraise plans
- →No explicit mention of new fundraising plans through debt or equity in the provided transcript.
- →The company reported having around Rs. 150 crores in fixed deposits and mutual funds as cash reserves.
- →CapEx plans include Rs. 200 crores for Phase-1 of the Patalganga project, funded likely through existing resources and internal accruals.
- →The company stated no utilization of working capital limits except for letters of credit and bank guarantees, indicating stable liquidity.
- →No direct comments on plans to raise new capital via debt or equity during the discussed period or in the near future.
Order book
Yes- →The company is scaling its CDMO-CMO business with promising progress.
- →They are very close to signing a term sheet for a large anesthetic CDMO contract, expected to be announced next quarter.
- →Qualification work and quality approvals for this contract are largely completed.
- →New product launches, including anesthetic liquids and cardiovascular drugs, are expected to contribute to order growth.
- →The company anticipates a robust product pipeline supporting sustained demand across various therapeutic segments.
- →Revenue target of approximately Rs. 1,000 crores by FY '27 remains on track, indicating strong order inflow.
- →Growth is expected to be non-linear, influenced by product ramp-ups and market conditions.
- →No explicit numerical figure on total current pending orders or backlog was provided within the disclosed pages.
Capex plans
Yes- →**Patalganga Facility Investment**: Phase-1 CapEx earmarked at around Rs. 200 crores, including two API/advanced intermediate blocks and two formulation blocks. Construction started with boundary walls already underway. API block prioritized initially due to nearing capacity exhaustion at the Lote site. Formulation blocks to be developed phase-wise (Page 4, 5, 12).
- →**Isambe Project**: Initial phase CapEx estimated at Rs. 200 crores with potential for larger investment in subsequent phases (Page 17).
- →**Ambernath Facility**: Depreciation expected at Rs. 14-15 crores annually; facility recently started contributing to revenue and scheduled for EU audit in November (Page 10, 12).
- →**Maintenance and Small Projects**: Ongoing smaller CapEx for maintenance, formulation plans, and scale-up (Page 5, 14).
- →**Automation and R&D Expansion**: Investments in R&D expansion and system implementations including SAP and quality management systems (Page 16, 19).
Track Supriya Lifescience Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- →Supriya Lifescience targets a revenue of around Rs. 1,000 crores by FY '27, reflecting strong demand and new product launches.
- →Management anticipates maintaining EBITDA margins in the range of 33% to 35% over the next 3-4 years.
- →PAT margin guidance stands around 25%.
- →Growth expected to be non-linear quarterly but robust over the medium term, supported by new therapies, vertical expansions (CMO-CDMO), and capacity additions like Patalganga facility.
- →CAGR growth of about 20% year-on-year expected beyond FY '27, with potential for acceleration depending on regulatory approvals and market traction.
- →Margin expansion beyond current levels unlikely in near term due to CMO-CDMO focus and semi-regulated market scale-up phases.
Order book
Yes- →The company is scaling its CDMO-CMO business with promising progress.
- →They are very close to signing a term sheet for a large anesthetic CDMO contract, expected to be announced next quarter.
- →Qualification work and quality approvals for this contract are largely completed.
- →New product launches, including anesthetic liquids and cardiovascular drugs, are expected to contribute to order growth.
- →The company anticipates a robust product pipeline supporting sustained demand across various therapeutic segments.
- →Revenue target of approximately Rs. 1,000 crores by FY '27 remains on track, indicating strong order inflow.
- →Growth is expected to be non-linear, influenced by product ramp-ups and market conditions.
- →No explicit numerical figure on total current pending orders or backlog was provided within the disclosed pages.
How does Supriya Lifescience Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Supriya Lifescience Ltd
Rev 2Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Supriya Lifescience Ltd rank in Pharmaceuticals & Biotechnology?
Compare Supriya Lifescience Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.